Abstract
We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer) trial. In this study, 442 untreated patients with advanced squamous cell carcinomas of the head and neck (SCCHN) were randomly assigned to receive platinum and 5-fluorouracil with or without cetuximab. Median overall survival the primary end point of the trial was improved in the cetuximab arm compared with the chemotherapy-alone arm (10.1 months and 7.4 months, respectively; P = 0.04). This is the first phase III trial in over two decades to exhibit a survival advantage in patients with SCCHN not amenable for curative treatment; however, it raises several considerations for clinical practice and future research directions, such as the optimum choice of chemotherapy to be combined with cetuximab, sequencing of cetuximab with chemotherapy, predictive markers of benefit from cetuximab, as well as implications for patients with locally advanced, potentially curable disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Licitra L et al. (2008) Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. Ann Oncol 19 (Suppl 7): vii200–vii203
Vermorken JB et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116–1127
Kies MS et al. (2006) Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN) [abstract #5520]. ASCO Meeting Abstracts 24: 5520
Tishler RB et al. (2008) Cetuximab added to docetaxel, cisplatin, 5-fluorouracil induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study [abstract #6001]. ASCO Meeting Abstracts 26: 6001
Kim ES et al. (2007) Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract #6013]. ASCO Meeting Abstracts 25: 6013
Ciardiello F and Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160–1174
Vermorken JB et al. (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171–2177
Bonner JA et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
ES Kim has received research funding from Genentech, ImClone Systems Inc. and OSI Pharmaceuticals, and RS Herbst has received research funding from Bristol-Myers Squibb and ImClone Systems Inc. WN William Jr declared no competing interests.
Rights and permissions
About this article
Cite this article
William, W., Kim, E. & Herbst, R. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nat Rev Clin Oncol 6, 132–133 (2009). https://doi.org/10.1038/ncponc1321
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1321
